Schellenberg Wittmer advised SIX Swiss Exchange-listed ams-OSRAM AG on the sale of its Passive Optical Components Assets. Focuslight Technologies Inc., a global provider of high-power diode...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Boerhringer Ingelheim on the deal. Boehringer Ingelheim has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the operation. Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Österreichische Bundesbahnen (ÖBB) on the deal. The ÖBB tour operator Rail Tours (Australian Railways) has joined the DER subsidiary Railtour Suisse in Switzerland...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Asker Healthcare Group on the deal. Asker Healthcare Group announced its acquisition of all shares in the Swiss medical supplies distributor Aichele Medico AG...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Avaloq Group on the deal. Avaloq Group announced its sale of Avaloq Outline AG, a global outsourcing provider for business process solutions and...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised GP Investments on the deal. GP Investments, Ltd. (GP Investments), majority shareholder of Spice Private Equity Ltd. (Spice Private Equity), has published on...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Julius Baer Group Ltd on the deal. Julius Baer has decided to sell Geneva-based Fransad Gestion SA (Fransad) to the management team of the...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Kinarus in this transaction. Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral,...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advises Julius Baer Group Ltd on the deal. Julius Baer has agreed to sell Wergen & Partner Wealth Management to its management. The parties...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised as local Swiss counsel Preqin Limited in the transaction. Preqin, the global leader in alternative assets data, analytics and insights, has acquired Colmore, a leading...
You must be a Standard 1 Year member to access this content.
Schellenberg Wittmer advised Julius Baer Group Ltd on the deal. As part of its market strategy for Switzerland, Julius Baer is extending its real estate offering...
You must be a Standard 1 Year member to access this content.
